Cardiac Failure Review最新文献_第5页

Why Do so Few People with Heart Failure Receive Cardiac Rehabilitation? 为什么心力衰竭患者很少接受心脏康复治疗?

Cardiac Failure Review Pub Date : 2022-09-23 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.16

David R Thompson, Chantal F Ski, Alexander M Clark, Hasnain M Dalal, Rod S Taylor

{"title":"Why Do so Few People with Heart Failure Receive Cardiac Rehabilitation?","authors":"David R Thompson, Chantal F Ski, Alexander M Clark, Hasnain M Dalal, Rod S Taylor","doi":"10.15420/cfr.2022.16","DOIUrl":"https://doi.org/10.15420/cfr.2022.16","url":null,"abstract":"Many people with heart failure do not receive cardiac rehabilitation despite a strong evidence base attesting to its effectiveness, and national and international guideline recommendations. A more holistic approach to heart failure rehabilitation is proposed as an alternative to the predominant focus on exercise, emphasising the important role of education and psychosocial support, and acknowledging that this depends on patient need, choice and preference. An individualised, needs-led approach, exploiting the latest digital technologies when appropriate, may help fill existing gaps, improve access, uptake and completion, and ensure optimal health and wellbeing for people with heart failure and their families. Exercise, education, lifestyle change and psychosocial support should, as core elements, unless contraindicated due to medical reasons, be offered routinely to people with heart failure, but tailored to individual circumstances, such as with regard to age and frailty, and possibly for recipients of cardiac implantable electronic devices or left ventricular assist devices.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e28"},"PeriodicalIF":0.0,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/c4/cfr-08-e28.PMC9585646.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40433214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Imaging in Women with Heart Failure: Sex-specific Characteristics and Current Challenges. 女性心力衰竭患者的成像：性别特征与当前挑战。

IF 4.2

Cardiac Failure Review Pub Date : 2022-09-23 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.17

Isabella Leo, Eleni Nakou, Antonio de Marvao, Joyce Wong, Chiara Bucciarelli-Ducci

引用次数: 0

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction. 保留射血分数心力衰竭的流行病学和临床特征。

Cardiac Failure Review Pub Date : 2022-08-04 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.06

Kanako Teramoto, Tiew-Hwa Katherine Teng, Chanchal Chandramouli, Jasper Tromp, Yasuhiko Sakata, Carolyn Sp Lam

引用次数: 14

Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. 钠-葡萄糖共转运蛋白2抑制剂在保留射血分数的心力衰竭中的应用:成功治疗的基本原理和实际应用。

Cardiac Failure Review Pub Date : 2022-07-08 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.04

Mauro Gori, Emilia D'Elia, Edoardo Sciatti, Michele Senni

{"title":"Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy.","authors":"Mauro Gori, Emilia D'Elia, Edoardo Sciatti, Michele Senni","doi":"10.15420/cfr.2022.04","DOIUrl":"https://doi.org/10.15420/cfr.2022.04","url":null,"abstract":"Heart failure (HF) with preserved left ventricular ejection fraction is a common disease with a poor prognosis and rising prevalence in the community. The current paradigm of treatment includes symptomatic therapy, such as diuretics, and risk factor control and treatment of comorbidities. According to European guidelines, there is no effective therapy for patients with HF with left ventricular ejection fraction (LVEF) ≥50%, while drugs normally used in HF with reduced LVEF might also be effective for patients with mildly reduced LVEF (40-50%), with a IIB class of recommendation. The recently published EMPEROR-Preserved trial has challenged current guidelines, demonstrating improved outcomes in patients with HF and LVEF >40% with the sodium-glucose cotransporter 2 inhibitor (SGLT2I) empagliflozin, compared with placebo. This result was consistent in patients with and without diabetes as well as in those with LVEF below and above 50%. The authors describe the rationale for this therapy, presenting the main results of the EMPEROR-Preserved trial, and provide some recommendations for the everyday clinical management of HF with preserved left ventricular ejection with an SGLT2I.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e26"},"PeriodicalIF":0.0,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/e9/cfr-08-e26.PMC9295008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40529358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unequitable Heart Failure Therapy for Black, Hispanic and American-Indian Patients. 黑人、西班牙裔和美国印第安人患者的不公平心力衰竭治疗。

Cardiac Failure Review Pub Date : 2022-07-07 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.02

Onyedika Ilonze, Kendall Free, Khadijah Breathett

引用次数: 14

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis. 射血分数保留型心力衰竭的微血管功能障碍：病理生理学、评估、发病率和预后。

IF 4.2

Cardiac Failure Review Pub Date : 2022-07-01 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.12

Joanna M Bilak, Uazman Alam, Christopher A Miller, Gerry P McCann, Jayanth R Arnold, Prathap Kanagala

引用次数: 0

Clinical Evidence and Proposed Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect? 钠-葡萄糖共转运蛋白2抑制剂在保留射血分数的心力衰竭中的临床证据和机制:一类效应?

Cardiac Failure Review Pub Date : 2022-06-29 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.11

Brent Deschaine, Sahil Verma, Hussein Rayatzadeh

{"title":"Clinical Evidence and Proposed Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?","authors":"Brent Deschaine, Sahil Verma, Hussein Rayatzadeh","doi":"10.15420/cfr.2022.11","DOIUrl":"https://doi.org/10.15420/cfr.2022.11","url":null,"abstract":"Effective treatment for heart failure with preserved ejection fraction (HFpEF) is an unmet need in cardiovascular medicine. The pathophysiological drivers of HFpEF are complex, differing depending on phenotype, making a one-size-fits-all treatment approach unlikely. Remarkably, sodium-glucose cotransporter 2 inhibitors (SGLT2is) may be the first drug class to improve cardiovascular outcomes in HFpEF. Randomised controlled trials suggest a benefit in mortality, and demonstrate decreased hospitalisations and improvement in functional status. Limitations in trials exist, either due to small sample sizes, differing results between trials or decreased efficacy at higher ejection fractions. SGLT2is may provide a class effect by targeting various pathophysiological HFpEF mechanisms. Inhibition of SGLT2 and Na+/H+ exchanger 3 in the kidney promotes glycosuria, osmotic diuresis and natriuresis. The glucose deprivation activates sirtuins - protecting against oxidation and beneficially regulating metabolism. SGLT2is reduce excess epicardial adipose tissue and its deleterious adipokines. Na+/H+ exchanger 1 inhibition in the heart and lungs reduces sodium-induced calcium overload and pulmonary hypertension, respectively.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e23"},"PeriodicalIF":0.0,"publicationDate":"2022-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/25/cfr-08-e23.PMC9272408.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40612958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. 指南指导的心力衰竭射血分数降低的药物治疗的医院内启动和上调。

IF 4.2

Cardiac Failure Review Pub Date : 2022-06-24 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2022.08

Zachary L Cox, Shuktika Nandkeolyar, Andrew J Johnson, JoAnn Lindenfeld, Aniket S Rali

引用次数: 0

The Role of Cardiac Imaging in Heart Failure with Reduced Ejection Fraction. 心脏造影在心力衰竭伴射血分数降低中的作用。

Cardiac Failure Review Pub Date : 2022-06-24 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2021.33

Rebecca C Gosling, Abdallah Al-Mohammad

引用次数: 1

Biomarkers in Heart Failure with Preserved Ejection Fraction. 保留射血分数的心力衰竭的生物标志物。

Cardiac Failure Review Pub Date : 2022-06-23 eCollection Date: 2022-01-01 DOI: 10.15420/cfr.2021.37

Antoni Bayes-Genis, Germán Cediel, Mar Domingo, Pau Codina, Evelyn Santiago, Josep Lupón

{"title":"Biomarkers in Heart Failure with Preserved Ejection Fraction.","authors":"Antoni Bayes-Genis, Germán Cediel, Mar Domingo, Pau Codina, Evelyn Santiago, Josep Lupón","doi":"10.15420/cfr.2021.37","DOIUrl":"https://doi.org/10.15420/cfr.2021.37","url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder developing from multiple aetiologies with overlapping pathophysiological mechanisms. HFpEF diagnosis may be challenging, as neither cardiac imaging nor physical examination are sensitive in this situation. Here, we review biomarkers of HFpEF, of which the best supported are related to myocardial stretch and injury, including natriuretic peptides and cardiac troponins. An overview of biomarkers of inflammation, extracellular matrix derangements and fibrosis, senescence, vascular dysfunction, anaemia/iron deficiency and obesity is also provided. Finally, novel biomarkers from -omics technologies, including plasma metabolites and circulating microRNAs, are outlined briefly. A cardiac-centred approach to HFpEF diagnosis using natriuretic peptides seems reasonable at present in clinical practice. A holistic approach including biomarkers that provide information on the non-cardiac components of the HFpEF syndrome may enrich our understanding of the disease and may be useful in classifying HFpEF phenotypes or endotypes that may guide patient selection in HFpEF trials.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e20"},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/bd/cfr-08-e20.PMC9253965.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40492041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12